You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Actim said the assay has 96 percent sensitivity and 98 percent specificity and it does not cross-react with IgG antibodies against other common viruses.
Oxford Immunotec's T-Spot Discovery SARC-CoV-2 test will be used to assess whether Valneva's vaccine candidate induces a T-cell response.
More than $19 billion will be given through the CDC Epidemiology and Laboratory Capacity cooperative agreement to support testing, contact tracing, and surveillance.
Moderna's vaccine triggers antibody response specifically to the anti-receptor binding domain antibodies of the SARS-CoV-2 spike protein.